Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026

– Response rates up to 50% across evaluated dose levels and median PFS of 13 months observed in pre-treated, cabozantinib-naïve, locally advanced or metastatic ccRCC patients –

– Activity compares favorably with historical outcomes for TKI and HIF-2α monotherapies -–

– Combination was well tolerated and safety profile consistent with reported profiles of the individual agents –

– Findings support potential for darlifarnib to enhance activity of VEGFR-targeted therapies in second- and third-line RCC settings –

– Global, randomized Phase 1b study underway to establish recommended Phase 3 dose –

– Investor call scheduled for today, July 27, 2026, at 5:00 a.m. PT / 8:00 a.m. ET –

SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, announced updated Phase 1a results from the ongoing FIT-001 clinical trial (NCT06026410) demonstrating encouraging and durable clinical activity of darlifarnib plus cabozantinib in cabozantinib-naïve patients with advanced clear cell renal cell carcinoma (ccRCC). The results were presented at the 2026 Kidney Cancer Research Summit (KCRS) in Boston and support continued development of the combination, including dose selection for the randomized Phase 1b portion of the study.

The long-term data compare favorably with benchmarks for advanced RCC, showing robust antitumor activity with darlifarnib plus cabozantinib, as well as evidence of durable benefit. The combination had a manageable safety profile across all dose levels, including when administered with full-dose cabozantinib.

Clinical Activity in Cabozantinib-naïve ccRCC Patients (N=34):

  • Objective response rate ranged from 33% to 50% across evaluated darlifarnib dose levels
  • Median progression free survival was 13 months across pooled dose levels
  • Median duration of response was not estimable at most dose levels assessed because multiple responses remain ongoing
  • Durable clinical benefit was observed across all evaluated combination dose levels, with more than half of patients remaining on treatment at data cut-off

Safety and Tolerability in RCC Patients (N=72):

  • The safety and tolerability profile was manageable and generally consistent with reported safety profiles of the individual agents
    • Supportive care, including for neutropenia, was not allowed during the dose-limiting toxicity study period
    • Neutropenia was successfully managed with dose interruption/reduction and supportive care (as allowed after the initial dose-limiting toxicity period)

“The response rates and progression-free survival observed with darlifarnib plus cabozantinib are encouraging in this refractory, pretreated, cabozantinib-naïve population, particularly given the limited treatment options after prior immunotherapy, immune check point inhibitors, and VEGFR-targeted therapy,” said Adanma Ayanambakkam, M.D., M.S., Assistant Professor of Hematology Oncology, Assistant Medical Director Clinical Trials Office, Stephenson Cancer Center, University of Oklahoma Health Sciences Center. “Continued follow-up will further define the durability of benefit.”

Duration of Treatment and Clinical Outcomes

Clinical benefit observed across combination dose levels, with multiple patients remaining on treatment.

“These updated Phase 1a data continue to support the potential for darlifarnib to enhance VEGFR-targeted therapy in advanced RCC and have informed the dose combinations advancing into the randomized Phase 1b portion of FIT-001,” said Mollie Leoni, M.D., Chief Medical Officer of Kura Oncology. “Cabozantinib-naïve patients represent an increasingly important treatment population as cabozantinib is often reserved for later lines of therapy following immunotherapy-based regimens. We look forward to longer follow-up from Phase 1a and randomized data from Phase 1b as we continue development toward a planned registrational study.”

Kura is currently enrolling patients in the U.S. and E.U. in the randomized Phase 1b dose-optimization portion of FIT-001 in cabozantinib-naïve, refractory ccRCC. The Phase 1b portion is evaluating darlifarnib plus cabozantinib versus cabozantinib alone and is designed to inform selection of a recommended Phase 3 dose for a planned registrational study in 2028.

Virtual Investor Event

Kura will host a webcast and conference call today, July 27, 2026, at 5:00 a.m. PT / 8:00 a.m. ET featuring management and Adanma Ayanambakkam, M.D., M.S., Assistant Professor of Hematology Oncology and Assistant Medical Director, Clinical Trials Office, Stephenson Cancer Center, University of Oklahoma Health Sciences Center. The live webcast and replay will be available on the Company’s website at www.kuraoncology.com under the Investors tab in the Events and Presentations section.

Abbreviations

HIF-2α, hypoxia-inducible factor 2 alpha; PD, progressive disease; PFS, progression-free survival; PR, partial response; RCC, renal cell carcinoma; SD, stable disease; TKI, tyrosine kinase inhibitor; VEGFR, vascular endothelial growth factor receptor

About Darlifarnib

Darlifarnib is a next-generation farnesyl transferase inhibitor (FTI) under development that inhibits farnesylation of RHEB, resulting in selective mTORC1 inhibition while sparing mTORC2. This mechanism has potential to enhance the activity of multiple targeted therapies where complementary inhibition of oncogenic pathways may improve clinical outcomes, including VEGFR-targeted therapies such as cabozantinib.

About Kura Oncology

Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.

Forward-Looking Statements 

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include, among other things, statements regarding the potential of darlifarnib to enhance the activity of cabozantinib and other VEGFR-targeted therapies in RCC and to improve clinical outcomes, the potential of darlifarnib in combination with cabozantinib to offer durable benefit to patients with RCC, and ongoing and planned clinical trials of darlifarnib in combination with cabozantinib. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Kura may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings, and other interactions with regulatory bodies, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties Kura faces, please refer to Kura’s periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Kura assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. 

Conflict of Interest Disclosure

Dr. Ayanambakkam’s disclosures include consulting or advisory roles with AVEO, Pfizer/Astellas; Johnson & Johnson; Kura Oncology: Travel, Accommodations, Expenses, and Research Funding; and Regeneron.

Kura Contact

Investors and Media:
Greg Mann
858-987-4046
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b3ffef56-a27c-4f7a-a629-51d913a2d1a3



Perfect Corp. Reports Unaudited Financial Results for the Three Months and Six Months Ended June 30, 2026

Perfect Corp. Reports Unaudited Financial Results for the Three Months and Six Months Ended June 30, 2026

NEW YORK–(BUSINESS WIRE)–
Perfect Corp. (NYSE: PERF) (“Perfect” or the “Company”), a leading artificial intelligence (“AI”) company offering AI and augmented reality (“AR”) powered solutions to beauty and fashion industries, today announced its unaudited financial results for the three months and six months ended June 30, 2026.

Highlights for the Three Months Ended June 30, 2026

  • Total revenue was $16.3 million for the three months ended June 30, 2026, remaining stable compared to the same period of 2025.
  • Gross profit was $13.2 million for the three months ended June 30, 2026, compared to $12.3 million in the same period of 2025, an increase of 7.4%.
  • Operating loss was $0.1 million for the three months ended June 30, 2026, compared to an operating loss of $1.5 million in the same period of 2025, representing an improvement of $1.4 million.
  • Netincome was $1.3 million for the three months ended June 30, 2026, compared to $0.2 million during the same period of 2025, an increase of 518.4%.

Ms. Alice H. Chang, Founder, Chairwoman, and Chief Executive Officer of Perfect Corp., commented, “Perfect Corp. continues to prioritize the advancement of our consumer (B2C) and enterprise (B2B) businesses through AI-driven innovation. While the rapid evolution of AI is creating both opportunities and challenges across the sector, ongoing demand for Generative AI and Agentic AI solutions reinforces our commitment to developing products and services that address these evolving needs. We also remain focused on strengthening our technology capabilities and expanding our solutions to pursue opportunities across both business segments.”

Financial Results for the Three Months Ended June 30, 2026

Revenue

Total revenue remained stable at $16.3 million for the three months ended June 30, 2026, compared to the same period of 2025, as continued growth in YouCam mobile app and web services subscriptions was offset by a decrease in licensing revenue.

  • AI- and AR- cloud solutions and subscription revenue remained relatively stable at $14.9 million for the three months ended June 30, 2026, compared to the same period of 2025. AI- and AR- cloud solutions and subscription revenue was primarily driven by the revenue growth from YouCam mobile app and web subscriptions, supported by growing popularity among consumers for Generative AI technologies and AI editing features for photos and videos.

  • Licensing revenue was $0.7 million for the three months ended June 30, 2026, compared to $1.0 million in the same period of 2025, a decrease of 25.3%. The Company anticipates that this legacy non-recurring revenue will become increasingly immaterial as it continues to prioritize enhancing its market leadership in the consumer beauty and AI mobile apps and web subscriptions as well as AI- and AR-based SaaS subscription solutions for brands and customers.

Gross Profit

Gross profit was $13.2 million for the three months ended June 30, 2026, compared with $12.3 million in the same period of 2025, an increase of 7.4%. Gross margin was 80.9% for the three months ended June 30, 2026, an increase from 75.3% in the same period of 2025. The increase in gross margin during the quarter was primarily due to the increase in operational efficiency resulting from the ongoing realignment of engineering professionals as we continue to transition from customization of software toward more standardized AI/API solutions for our customer base.

Total Operating Expenses

Total operating expenses were $13.3 million for the three months ended June 30, 2026, compared with $13.8 million in the same period of 2025, a decrease of 3.2%. The decrease was primarily due to decreases in research and development and general and administrative expenses in the second quarter of 2026.

  • Sales and marketing expenses remained stable at $7.8 million for the three months ended June 30, 2026, compared to the same period of 2025.
  • Research and development expenses were $3.6 million for the three months ended June 30, 2026, compared to $4.0 million during the same period of 2025, a decrease of 11.0%. This decrease was primarily due to reduction of engineering resources by creating better synergies among different product development teams.
  • General and administrative expenses were at $1.9 million for the three months ended June 30, 2026, and compared to $2.0 million for the same period of 2025, a decrease of 6.9%, demonstrating our effective cost control.

Total Operating Loss

Total operating loss narrowed to $0.1 million for the three months ended June 30, 2026, compared to $1.5 million during the same period of 2025. The improvement in operating results was primarily driven by higher gross profit, while operating expenses remained steady.

Net Income

Net income was $1.3 million for the three months ended June 30, 2026, compared to $0.2 million during the same period of 2025. The significant increase in net income was primarily due to improved gross margin, increase in gains on financial liabilities and lower operating expenses resulting from effective cost control.

Operating Cash Flow

Operating cash flow was $1.0 million in the three months ended June 30, 2026, compared to $3.7 million in the same period of 2025, a decrease of 73.6%. This decrease was primarily due to fewer current contract liabilities and higher income tax paid, partially offset by higher profit before tax.

Financial Results for the Six Months Ended June 30, 2026

Revenue

Total revenue was $34.3 million for the six months ended June 30, 2026, compared to $32.4 million in the same period of 2025, an increase of 5.9%.

  • AI- and AR- cloud solutions and subscription revenue was $30.4 million for the six months ended June 30, 2026, compared to $29.0 million in the same period of 2025, an increase of 5.0%. The increase was primarily driven by the continued revenue growth from YouCam mobile app and web subscriptions, supported by growing popularity among consumers for Generative AI technologies and AI editing features for photos and videos.

  • Licensing revenue was $2.2 million for the six months ended June 30, 2026, compared to $2.6 million in the same period of 2025, a decrease of 13.2%.

Gross Profit

Gross profit was $27.9 million for the six months ended June 30, 2026, compared with $24.8 million in the same period of 2025, an increase of 12.7%. Gross margin was 81.5% for the six months ended June 30, 2026, an increase from 76.6% in the same period of 2025. The increase in gross margin during the first half of 2026 was primarily due to the increase in operational efficiency by supplying standardized SaaS solutions with fewer brand-specific customization efforts.

Total Operating Expenses

Total operating expenses were $26.6 million for the six months ended June 30, 2026, compared with $26.4 million in the same period of 2025, an increase of 0.6%.

  • Sales and marketing expenses remained relatively stable at $15.5 million for the six months ended June 30, 2026, compared to $15.2 million during the same period of 2025.
  • Research and development expenses was $7.1 million for the six months ended June 30, 2026, compared to $7.6 million during the same period of 2025, a slight decrease of 6.3%.
  • General and administrative expenses were at $3.6 million for the six months ended June 30, 2026, and compared to $3.7 million for the same period of 2025, a slight decrease of 3.1%, demonstrating our effective cost control.

Total Operating Income/Loss

Total operating income was $1.4 million for the six months ended June 30, 2026, compared to an operating loss of $1.6 million during the same period of 2025. The swing to profitability was primarily driven by higher gross profit, while operating expenses grew only modestly.

Net Income

Net income was $3.6 million for the six months ended June 30, 2026, compared to $2.5 million during the same period of 2025, an increase of 45.3%. The positive net income was supported by our steady revenue growth and effective cost control.

Operating Cash Flow

Operating cash inflow was $5.2 million in the six months ended June 30, 2026, compared to $8.0 million in the same period of 2025, a decrease of 34.8%. The decrease was primarily driven by lower current contract liabilities and higher income tax paid. The Company continues to invest in growth while maintaining a positive operating cash flow to support business operations.

Liquidity and Capital Resource

As of June 30, 2026, the Company’s cash and cash equivalents remained stable at $125.6 million (or $177.1 million when including 6-month time deposits of $36.4 million and US Treasuries of $15.1 million, which are classified as current and non-current financial assets at amortized cost under IFRS, respectively), compared to $120.6 million (or $176.4 million when including time deposits, US Treasuries and money market funds) as of March 31, 2026.

Key Business Metrics

  • The number of active subscribers for the Company’s YouCam mobile beauty apps and web services was 820,000 as of June 30, 2026, compared to over 960,000 as of June 30, 2025, a decrease of 14.6%. The decline was attributable to the increased competition through the rapidly shifting landscape of AI driven apps.

  • The number of Key Customers1 of the Company as of June 30, 2026 was 113 compared to 139 as of June 30, 2025. The net decline in the number of Key Customers was primarily due to customer downgrades in service subscription spending.

Recent Development

On March 18, 2026, Perfect announced receipt of preliminary non-binding “Going Private” proposal.

On March 23, 2026, Perfect’s Board announced the formation of special committee to evaluate on the preliminary non-binding “Going Private” proposal received on March 18, 2026.

On April 20, 2026, Perfect announced appointment of financial advisor and legal counsel to the special committee.

On July 10, 2026, Perfect announced that it has entered into a Definitive Agreement for a Going-Private Transaction.

About Perfect Corp.

Founded in 2015, Perfect Corp. is a leading AI company offering self-developed AI- and AR- powered solutions dedicated to transforming the world with digital tech innovations that make your virtual world beautiful. On Perfect’s direct consumer business side, Perfect operates a family of YouCam consumer apps and web-editing services for photo, video and camera users, centered on unleashing creativity with AI-driven features for creation, beautification and enhancement. On Perfect’s enterprise business side, Perfect empowers major beauty, skincare, fashion, jewelry, and watch brands and retailers by supplying them with omnichannel shopping experiences through AR product try-ons and AI-powered skin diagnostics. With cutting-edge technologies such as Generative AI, real-time facial and hand 3D AR rendering and cloud solutions, Perfect enables personalized, enjoyable, and engaging shopping journey and helps brands elevate customer engagement, increase conversion rates, and propel sales growth. Throughout this journey, Perfect maintains its unwavering commitment to environmental sustainability and fulfilling social responsibilities. For more information, visit https://ir.perfectcorp.com/.

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, or the Exchange Act, that are based on beliefs and assumptions and on information currently available to Perfect. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” “target,” “seek” or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Any statements that refer to expectations, projections or other characterizations of future events or circumstances, including strategies or plans, are also forward-looking statements. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. These statements are based on Perfect’s reasonable expectations and beliefs concerning future events and involve risks and uncertainties that may cause actual results to differ materially from current expectations. These factors are difficult to predict accurately and may be beyond Perfect’s control. Forward-looking statements in this communication or elsewhere speak only as of the date made. New uncertainties and risks arise from time to time, and it is impossible for Perfect to predict these events or how they may affect Perfect. In addition, risks and uncertainties are described in Perfect’s filings with the Securities and Exchange Commission. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Perfect cannot assure you that the forward-looking statements in this communication will prove to be accurate. There may be additional risks that Perfect presently does not know or that Perfect currently does not believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by Perfect, its directors, officers or employees or any other person that Perfect will achieve its objectives and plans in any specified time frame, or at all. Except as required by applicable law, Perfect does not have any duty to, and does not intend to, update or revise the forward-looking statements in this communication or elsewhere after the date of this communication. You should, therefore, not rely on these forward-looking statements as representing the views of Perfect as of any date subsequent to the date of this communication.

____________________

1

“Key Customers” refers to the Company’s brand customers who contributed revenue of more than $50,000 in the trailing 12 months ended on the measurement date.

PERFECT CORP. AND SUBSIDIARIES

UNAUDITED CONSOLIDATED BALANCE SHEETS

DECEMBER 31, 2025 AND JUNE 30, 2026

(Expressed in thousands of United States dollars)

 

 

 

December 31,

2025

 

June 30,

2026

Assets

 

Amount

 

Amount

Current assets

 

 

 

 

Cash and cash equivalents

 

$

125,976

 

$

125,621

Current financial assets at amortized cost

 

 

36,300

 

 

36,400

Current contract assets

 

 

968

 

 

934

Accounts receivable

 

 

7,567

 

 

5,955

Other receivables

 

 

358

 

 

423

Current income tax assets

 

 

22

 

 

22

Inventories

 

 

17

 

 

16

Other current assets

 

 

2,138

 

 

1,706

Total current assets

 

 

173,346

 

 

171,077

Non-current assets

 

 

 

 

Non-current financial assets at amortized cost

 

 

10,173

 

 

15,122

Property, plant and equipment

 

 

695

 

 

625

Right-of-use assets

 

 

659

 

 

625

Intangible assets

 

 

4,421

 

 

4,360

Deferred income tax assets

 

 

2,483

 

 

2,641

Guarantee deposits paid

 

 

193

 

 

170

Total non-current assets

 

 

18,624

 

 

23,543

Total assets

 

$

191,970

 

$

194,620

 

(Continued)

PERFECT CORP. AND SUBSIDIARIES

UNAUDITED CONSOLIDATED BALANCE SHEETS (continued)

DECEMBER 31, 2025 AND JUNE 30, 2026

(Expressed in thousands of United States dollars)

 

 

 

December 31,

2025

 

June 30,

2026

Liabilities and Equity

 

Amount

 

Amount

Current liabilities

 

 

 

 

Current contract liabilities

 

$

21,902

 

 

$

20,441

 

Other payables

 

 

12,831

 

 

 

13,395

 

Other payables – related parties

 

 

72

 

 

 

62

 

Current tax liabilities

 

 

996

 

 

 

897

 

Current provisions

 

 

1,061

 

 

 

1,307

 

Current lease liabilities

 

 

444

 

 

 

478

 

Other current liabilities

 

 

359

 

 

 

375

 

Total current liabilities

 

 

37,665

 

 

 

36,955

 

Non-current liabilities

 

 

 

 

Non-current financial liabilities at fair value through profit or loss

 

 

419

 

 

 

27

 

Deferred income tax liabilities

 

 

488

 

 

 

470

 

Non-current lease liabilities

 

 

239

 

 

 

166

 

Net defined benefit liability, non-current

 

 

64

 

 

 

63

 

Total non-current liabilities

 

 

1,210

 

 

 

726

 

Total liabilities

 

 

38,875

 

 

 

37,681

 

 

 

 

 

 

Equity

 

 

 

 

Capital stock

 

 

 

 

Perfect Class A Ordinary Shares, $0.1 (in dollars) par value

 

 

8,506

 

 

 

8,506

 

Perfect Class B Ordinary Shares, $0.1 (in dollars) par value

 

 

1,679

 

 

 

1,679

 

Capital surplus

 

 

 

 

Capital surplus

 

 

514,400

 

 

 

514,687

 

Retained earnings

 

 

 

 

Accumulated deficit

 

 

(370,793

)

 

 

(367,160

)

Other equity interest

 

 

 

 

Other equity interest

 

 

(697

)

 

 

(773

)

Total equity

 

 

153,095

 

 

 

156,939

 

Total liabilities and equity

 

$

191,970

 

 

$

194,620

 

PERFECT CORP. AND SUBSIDIARIES

UNAUDITED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

FOR THE THREE MONTHS AND SIX MONTHS ENDED JUNE 30, 2025 AND 2026

(Expressed in thousands of United States dollars)

 

 

 

Three months ended June 30

 

Six months ended June 30

 

 

2025

 

2026

 

2025

 

2026

Items

 

Amount

 

Amount

 

Amount

 

Amount

Revenue

 

$

16,347

 

 

$

16,339

 

 

$

32,361

 

 

$

34,275

 

Cost of sales and services

 

 

(4,040

)

 

 

(3,116

)

 

 

(7,580

)

 

 

(6,358

)

Gross profit

 

 

12,307

 

 

 

13,223

 

 

 

24,781

 

 

 

27,917

 

Operating expenses

 

 

 

 

 

 

 

 

Sales and marketing expenses

 

 

(7,810

)

 

 

(7,826

)

 

 

(15,170

)

 

 

(15,476

)

General and administrative expenses

 

 

(2,001

)

 

 

(1,862

)

 

 

(3,707

)

 

 

(3,593

)

Research and development expenses

 

 

(4,030

)

 

 

(3,587

)

 

 

(7,595

)

 

 

(7,119

)

Expected credit losses (gains)

 

 

67

 

 

 

(56

)

 

 

67

 

 

 

(363

)

Total operating expenses

 

 

(13,774

)

 

 

(13,331

)

 

 

(26,405

)

 

 

(26,551

)

Operating income (loss)

 

 

(1,467

)

 

 

(108

)

 

 

(1,624

)

 

 

1,366

 

Non-operating income and expenses

 

 

 

 

 

 

 

 

Interest income

 

 

1,587

 

 

 

1,459

 

 

 

3,164

 

 

 

2,816

 

Other income

 

 

14

 

 

 

13

 

 

 

16

 

 

 

33

 

Other gains and losses

 

 

526

 

 

 

317

 

 

 

1,592

 

 

 

304

 

Finance costs

 

 

(3

)

 

 

(5

)

 

 

(6

)

 

 

(9

)

Total non-operating income and expenses

 

 

2,124

 

 

 

1,784

 

 

 

4,766

 

 

 

3,144

 

Income before income tax

 

 

657

 

 

 

1,676

 

 

 

3,142

 

 

 

4,510

 

Income tax expense

 

 

(450

)

 

 

(396

)

 

 

(642

)

 

 

(877

)

Net income

 

$

207

 

 

$

1,280

 

 

$

2,500

 

 

$

3,633

 

 

 

 

 

 

 

 

 

 

Other comprehensive income

 

 

 

 

 

 

 

 

Components of other comprehensive income that will be reclassified to profit or loss

 

 

 

 

 

 

 

 

Exchange differences arising on translation of foreign operations

 

$

103

 

 

$

(31

)

 

$

211

 

 

$

(76

)

Other comprehensive income, net

 

$

103

 

 

$

(31

)

 

$

211

 

 

$

(76

)

Total comprehensive income

 

$

310

 

 

$

1,249

 

 

$

2,711

 

 

$

3,557

 

Net income, attributable to:

 

 

 

 

 

 

 

 

Shareholders of the parent

 

$

207

 

 

$

1,280

 

 

$

2,500

 

 

$

3,633

 

Total comprehensive income attributable to:

 

 

 

 

 

 

 

 

Shareholders of the parent

 

$

310

 

 

$

1,249

 

 

$

2,711

 

 

$

3,557

 

Earnings per share (in dollars)

 

 

 

 

 

 

 

 

Basic earnings per share of Class A and Class B Ordinary Shares

 

$

0.002

 

 

$

0.013

 

 

$

0.025

 

 

$

0.036

 

Diluted earnings per share of Class A and Class B Ordinary Shares

 

$

0.002

 

 

$

0.013

 

 

$

0.025

 

 

$

0.036

 

PERFECT CORP. AND SUBSIDIARIES

UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE THREE MONTHS AND SIX MONTHS ENDED JUNE 30, 2025 AND 2026

(Expressed in thousands of United States dollars)

 

 

 

Three months ended June 30

 

Six months ended June 30

 

 

2025

 

2026

 

2025

 

2026

Items

 

Amount

 

Amount

 

Amount

 

Amount

CASH FLOWS FROM OPERATING ACTIVITIES

 

 

 

 

 

 

 

 

Profit before tax

 

$

657

 

 

$

1,676

 

 

$

3,142

 

 

$

4,510

 

Adjustments to reconcile profit (loss)

 

 

 

 

 

 

 

 

Depreciation expense

 

 

217

 

 

 

216

 

 

 

427

 

 

 

433

 

Amortization expense

 

 

44

 

 

 

30

 

 

 

75

 

 

 

61

 

Expected credit losses (Reversal of expected credit losses)

 

 

(67

)

 

 

56

 

 

 

(67

)

 

 

363

 

Interest income

 

 

(1,587

)

 

 

(1,459

)

 

 

(3,164

)

 

 

(2,816

)

Interest expense

 

 

3

 

 

 

5

 

 

 

6

 

 

 

9

 

Net gains on financial assets at fair value through profit or loss

 

 

(9

)

 

 

(9

)

 

 

(9

)

 

 

(26

)

Net gains on financial liabilities at fair value through profit or loss

 

 

(85

)

 

 

(282

)

 

 

(1,036

)

 

 

(392

)

Share-based payment transactions

 

 

280

 

 

 

73

 

 

 

900

 

 

 

287

 

Changes in operating assets and liabilities

 

 

 

 

 

 

 

 

Accounts receivable

 

 

456

 

 

 

721

 

 

 

(359

)

 

 

1,243

 

Current contract assets

 

 

(88

)

 

 

(137

)

 

 

126

 

 

 

24

 

Other receivables

 

 

(22

)

 

 

55

 

 

 

(22

)

 

 

 

Other current assets

 

 

148

 

 

 

237

 

 

 

362

 

 

 

433

 

Current contract liabilities

 

 

333

 

 

 

(2,563

)

 

 

4,309

 

 

 

(1,432

)

Other payables

 

 

2,137

 

 

 

1,606

 

 

 

1,493

 

 

 

576

 

Other payables – related parties

 

 

10

 

 

 

(49

)

 

 

16

 

 

 

(10

)

Current provisions

 

 

81

 

 

 

100

 

 

 

(519

)

 

 

257

 

Other current liabilities

 

 

(34

)

 

 

40

 

 

 

(47

)

 

 

19

 

Cash inflow generated from operations

 

 

2,474

 

 

 

316

 

 

 

5,633

 

 

 

3,539

 

Interest received

 

 

1,765

 

 

 

1,701

 

 

 

3,181

 

 

 

2,838

 

Interest paid

 

 

(3

)

 

 

(5

)

 

 

(6

)

 

 

(9

)

Income tax paid

 

 

(575

)

 

 

(1,045

)

 

 

(821

)

 

 

(1,159

)

Net cash flows from operating activities

 

 

3,661

 

 

 

967

 

 

 

7,987

 

 

 

5,209

 

CASH FLOWS FROM INVESTING ACTIVITIES

 

 

 

 

 

 

 

 

Acquisition of financial assets at fair value through profit or loss

 

 

(6,143

)

 

 

 

 

 

(6,143

)

 

 

(6,287

)

Proceeds from disposal of financial assets at fair value through profit or loss

 

 

 

 

 

4,242

 

 

 

2,746

 

 

 

6,313

 

Acquisition of financial assets at amortized cost

 

 

(30,000

)

 

 

(25,000

)

 

 

(36,300

)

 

 

(41,436

)

Proceeds from disposal of financial assets at amortized cost

 

 

30,000

 

 

 

25,000

 

 

 

36,000

 

 

 

36,300

 

Acquisition of subsidiaries, net of cash acquired

 

 

(428

)

 

 

 

 

 

(5,981

)

 

 

 

Acquisition of property, plant and equipment

 

 

(119

)

 

 

(39

)

 

 

(165

)

 

 

(95

)

Proceeds from disposal of property, plant and equipment

 

 

1

 

 

 

 

 

 

1

 

 

 

1

 

(Increase) Decrease in guarantee deposits paid

 

 

(15

)

 

 

(3

)

 

 

(67

)

 

 

23

 

Net cash flows from (used in) investing activities

 

 

(6,704

)

 

 

4,200

 

 

 

(9,909

)

 

 

(5,181

)

CASH FLOWS FROM FINANCING ACTIVITIES

 

 

 

 

 

 

 

 

Repayment of principal portion of lease liabilities

 

 

(169

)

 

 

(139

)

 

 

(303

)

 

 

(274

)

Net cash flows used in financing activities

 

 

(169

)

 

 

(139

)

 

 

(303

)

 

 

(274

)

Effects of exchange rates changes on cash and cash equivalents

 

 

246

 

 

 

(40

)

 

 

441

 

 

 

(109

)

Net increase (decrease) in cash and cash equivalents

 

 

(2,966

)

 

 

4,988

 

 

 

(1,784

)

 

 

(355

)

Cash and cash equivalents at beginning of period

 

 

128,303

 

 

 

120,633

 

 

 

127,121

 

 

 

125,976

 

Cash and cash equivalents at end of period

 

$

125,337

 

 

$

125,621

 

 

$

125,337

 

 

$

125,621

 

 

Investor Relations Contact

Investor Relations, Perfect Corp.

Email: [email protected]

Category: Investor Relations

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Technology Fashion Cosmetics Apps/Applications Photography Retail Software Artificial Intelligence Audio/Video Internet Mobile/Wireless

MEDIA:

Logo
Logo

Oklo Announces Date for Second Quarter 2026 Financial Results and Business Update Call

Oklo Announces Date for Second Quarter 2026 Financial Results and Business Update Call

SANTA CLARA, Calif.–(BUSINESS WIRE)–Oklo Inc. (NYSE: OKLO) (“Oklo,” or “the Company”), an advanced nuclear technology company, today announced it will release its financial results and provide business updates for the second quarter ended June 30, 2026, before market opens on Friday, August 7, 2026, followed by a conference call at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time).

Jacob DeWitte, co-founder and Chief Executive Officer, and Craig Bealmear, Chief Financial Officer, will participate in the call.

Webcast Details:

Date: Friday, August 7, 2026
Time: 8:30 a.m. Eastern Time
Webcast: https://events.q4inc.com/attendee/883212218 (live and replay)
North America Toll-Free: +1 833-461-5787
International Toll: +1 585-542-9983
Regional Dial-Ins: https://help.events.q4inc.com/eahc/international-dial-in-numbers
Meeting ID: 883 212 218

The webcast will be broadcast live and available for replay. A copy of the investor presentation and financial results will be available on Oklo’s website at https://oklo.com/investors, providing additional insights into the company’s performance and strategic direction.

About Oklo Inc.: Oklo Inc. is developing fast fission power plants to deliver clean, reliable, affordable energy at global scale; establishing a domestic supply chain for critical isotopes; and advancing nuclear fuel recycling to convert used nuclear fuel into clean energy. Oklo was the first to receive a site use permit from the U.S. Department of Energy for a commercial advanced fission plant, was awarded fuel from Idaho National Laboratory, and submitted the first custom combined license application for an advanced reactor to the U.S. Nuclear Regulatory Commission. Oklo is also developing advanced fuel recycling technologies in collaboration with the U.S. Department of Energy and U.S. National Laboratories.

Forward-Looking Statements

This press release includes statements that express Oklo’s opinions, expectations, objectives, beliefs, plans, intentions, strategies, assumptions, forecasts or projections regarding future events or future results and therefore are, or may be deemed to be, “forward-looking statements.” The words “may,” “will,” “could,” “should,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “continue,” “might,” “possible,” “potential,” “predict,” “project,” “goal,” “would,” “commit,” or, in each case, their negative or other variations or comparable terminology, and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this press release and include statements regarding our intentions, beliefs or current expectations concerning, among other things, results of operations, financial condition, liquidity, prospects, growth, strategies and the markets in which Oklo operates. Such forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties.

As a result of a number of known and unknown risks and uncertainties, the actual results or performance of Oklo may be materially different from those expressed or implied by these forward-looking statements. The following important risk factors could affect Oklo’s future results and cause those results or other outcomes to differ materially from those expressed or implied in the forward-looking statements: risks related to the development and deployment of Oklo’s powerhouses, fuel fabrication and fuel recycling facilities, and radioisotope production activities; the risk that Oklo is pursuing an emerging market with no commercial project operating and regulatory uncertainties; risks related to acquisitions, divestitures, or joint ventures we may engage in; the need for financing to construct plants, which remain subject to market, financial, political, and legal conditions; risks related to an inability to raise additional capital to support our business and sustain our growth on favorable terms; the effects of competition; risks related to accessing high-assay low-enriched uranium, plutonium, and other fuels (including recycled fuels) at acceptable costs and under acceptable timelines; risks related to our supply chain; risks related to power purchase agreements; risks related to human capital; risks related to our intellectual property; risks related to cybersecurity and data privacy; changes in applicable laws or regulations, including tariffs; the outcome of any government and regulatory proceedings and investigations and inquiries; and the other factors set forth in our documents we have filed with the U.S. Securities and Exchange Commission (the “SEC”).

The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties of the other documents filed by Oklo from time to time with the SEC. The forward-looking statements contained in this press release are based on current expectations and beliefs concerning future developments and their potential effects on Oklo. There can be no assurance that future developments affecting Oklo will be those that Oklo has anticipated. Oklo undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date of this presentation, except as may be required by law.

Media and Communications for Oklo:
Bonita Chester, Head of Communications and Media at [email protected]

Investor Contact:
Sam Doane, Senior Director of Investor Relations at [email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Software Utilities Hardware Alternative Energy Energy Technology Nuclear Security

MEDIA:

Logo
Logo

CorVel Corporation to Host Live Earnings Release Webcast

FORT WORTH, Texas, July 27, 2026 (GLOBE NEWSWIRE) — CorVel Corporation (NASDAQ: CRVL), a leading provider of innovative risk management solutions, is pleased to announce that it will host a live webcast to discuss its upcoming quarterly earnings results on Wednesday, August 5, 2026, at 11:30 AM Eastern Time.

The webcast will feature a discussion of CorVel’s financial performance, strategic initiatives, and outlook, led by Michael Combs, Executive Chairman, Sarah Scott, President and Chief Executive Officer, and Brian Nichols, Chief Financial Officer. The event will also include a dedicated question-and-answer session for attendees.

Webcast Details:

Investors, analysts, and interested parties are encouraged to join the webcast to gain insights into CorVel’s performance. Questions may be submitted in advance to [email protected].

About CorVel

CorVel Corp. applies technology, including artificial intelligence, machine learning, and natural language processing, to enhance the management of episodes of care and related health care costs. We partner with employers, third-party administrators, insurance companies, and government agencies in managing workers’ compensation and health, auto, and liability services. Our diverse suite of solutions combines our integrated technologies with a human touch. CorVel’s customized services, delivered locally, are backed by a national team to support our partners and their customers and patients.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

All statements included in this press release, other than statements or characterizations of historical fact, are forward-looking statements. These forward-looking statements are based on the Company’s current expectations, estimates and projections about the Company, management’s beliefs, and certain assumptions made by the Company, and events beyond the Company’s control, all of which are subject to change.   These forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause the Company’s actual results to differ materially and adversely from those expressed in any forward-looking statement results of operations and financial condition is greater than our initial assessment.  The risks and uncertainties referred to above include but are not limited to factors described in this press release and the Company’s filings with the Securities and Exchange Commission, including but not limited to “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended March 31, 2025, and the Company’s Quarterly Report on Form 10-Q for the quarters ended June 30, 2025 and September 30, 2025. The forward-looking statements in this press release speak only as of the date they are made. The Company undertakes no obligation to revise or update publicly any forward-looking statement for any reason.

Contact: Melissa Storan
Phone: 949-851-1473

www.corvel.com



PGIM to Acquire Remaining Interest in Deerpath Capital

PGIM to Acquire Remaining Interest in Deerpath Capital

Full ownership will create a more comprehensive direct lending platform across the middle market and large cap segments

NEWARK, N.J.–(BUSINESS WIRE)–
PGIM has agreed to acquire the remaining 25% interest in Deerpath Capital; bringing the firm’s ownership to 100%. This transaction follows PGIM’s initial acquisition of a 75% stake announced in May 2023 and is subject to regulatory approval.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260727723428/en/

“We continue to believe the traditional middle market remains an attractive and important segment for borrowers and investors.” --Matt Harvey, Global Head of Middle Market Direct Lending, PGIM

“We continue to believe the traditional middle market remains an attractive and important segment for borrowers and investors.” –Matt Harvey, Global Head of Middle Market Direct Lending, PGIM

The acquisition will strengthen PGIM’s direct lending platform by adding Deerpath Capital’s lower middle market expertise to PGIM’s existing core middle market and large cap capabilities. With the addition of Deerpath’s lower middle market platform, PGIM will be positioned among a select group of asset managers with capabilities across the direct lending spectrum, with a combined $16B in AUM across a team of 55 investment professionals.*

“As direct lenders have scaled, many have moved into the large cap segment. We continue to believe the traditional middle market remains an attractive and important segment for borrowers and investors,” said Matt Harvey, PGIM’s global head of middle market direct lending. “By moving to full ownership of Deerpath Capital, we are creating a more coordinated and scaled direct lending platform while preserving the investment discipline that has underpinned Deerpath Capital’s success. That combination better positions us to serve sponsors, borrowers and investors across the direct lending spectrum.”

The comprehensive platform will allow for continued support of private equity sponsored and non-sponsored businesses as they grow and transition across the middle market and large cap market over time. More broadly, full ownership is expected to strengthen sponsor coverage and coordination while supporting more tailored direct lending solutions across borrower size segments and cohesive investor distribution and client service.

Deerpath Capital CEO James Kirby commented: “As one of the world’s leading asset managers, PGIM is an ideal home for Deerpath, combining deep capital resources, asset management expertise and global relationships. Tas and I have developed an excellent working relationship with our colleagues at PGIM, and we look forward to the next chapter as part of the comprehensive PGIM Credit platform.”

James Kirby and Tas Hasan will continue to lead the Deerpath investment process and investment committee governance for Deerpath funds while assuming leadership roles in PGIM Credit.

James Kirby will contribute investment strategy thought leadership across middle market direct lending. Matt Harvey and Tas Hasan will lead the middle market direct lending platform together. The transaction will not alter Deerpath’s existing investment team capabilities, investment process or approach to underwriting.

ABOUT PGIM

PGIM is the global asset management business of Prudential Financial, Inc. (NYSE: PRU), with $1.4 trillion in assets under management.* PGIM offers clients deep expertise across public and private asset classes, delivering a diverse range of investment strategies and tailored solutions—including fixed income, equities, real estate and alternatives. With 1,500+ investment professionals across 40 offices in 20 countries, we serve retail and institutional clients worldwide. For more information, visit pgim.com.

Prudential Financial, Inc. (PFI) of the United States is not affiliated in any manner with Prudential plc, incorporated in the United Kingdom or with Prudential Assurance Company, a subsidiary of M&G plc, incorporated in the United Kingdom. For more information please visit news.prudential.com.

ABOUT DEERPATH CAPITAL MANAGEMENT, L.P

Deerpath Capital is an established private credit manager providing customized, cash-flow-based senior debt financing to sponsor-backed U.S. lower middle market companies. With a singular focus on this segment for nearly two decades, the firm has invested over $15 billion across more than 1,200 transactions and manages more than $9 billion in AUM as of March 31, 2026. Deerpath operates through regional origination and underwriting teams in the U.S. which are supported by global investor coverage across major U.S. markets, the U.K., Europe, Australia, Japan, Korea, and the Middle East. The firm’s focused strategy, deep lower middle market expertise, long-standing sponsor relationships, disciplined credit philosophy, and comprehensive direct lending platform define the Deerpath Difference. For more information, please visit www.deerpathcapital.com.

* As of Mar. 31, 2026.

The information contained herein is provided by PGIM, the principal asset management business of Prudential Financial, Inc. (PFI), and a trading name of PGIM, Inc. and its global subsidiaries and affiliates.

Please visit the Important Disclosures page on PGIM.com for additional information.

This information is for informational purposes only and does not constitute investment advice, a recommendation, or a solicitation where prohibited. Certain information has been obtained from sources that PGIM believes to be reliable as of the date presented; however, PGIM does not guarantee its accuracy or completeness. Information may be changed without notice, and PGIM has no obligation to update it.

PGIM and its affiliates may develop and publish research that is independent of and different from the information contained herein.

© 2026 Prudential Financial, Inc. (PFI) and its related entities. All rights reserved.

CONNECT WITH US:

Visit pgim.com

Follow on LinkedIn

MEDIA CONTACT

Guy Nicholls

+1 973 204 1648

[email protected]

KEYWORDS: New Jersey United States North America

INDUSTRY KEYWORDS: Banking Asset Management Professional Services Finance

MEDIA:

Photo
Photo
“We continue to believe the traditional middle market remains an attractive and important segment for borrowers and investors.” –Matt Harvey, Global Head of Middle Market Direct Lending, PGIM
Photo
Photo
“PGIM is an ideal home for Deerpath, combining deep capital resources, asset management expertise and global relationships.” –James Kirby, CEO, Deerpath Capital
Logo
Logo

The Ensign Group Reports Second Quarter 2026 Results

Raises 2026 Annual Earnings and Revenue Guidance;


Conference Call and Webcast scheduled for July 29, 2026 at 10:00 am PT

SAN JUAN CAPISTRANO, Calif., July 27, 2026 (GLOBE NEWSWIRE) — The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign(TM) group of companies, which provide post-acute healthcare services and invest in the long-term healthcare industry, primarily in skilled nursing and senior living facilities, announced operating results for the second quarter ended June 30, 2026, reporting GAAP diluted earnings per share of $1.68 and adjusted earnings per share(1) of $1.92.

“This quarter’s results are another reflection of that enduring connection between the commitment of our local leaders to delivering high-quality care in their communities and our financial performance. We believe exceptional outcomes ultimately create their own form of accountability, because residents, families, referral partners, regulators, and payers all independently validate whether an operation is truly delivering value,” said Barry Port, Chief Executive Officer of The Ensign Group. “We continue to see strong demand across our portfolio, improving occupancy and skilled mix. We also continue to grow in a disciplined way through acquisitions. We believe our results this quarter position us well for the remainder of the year and reinforce our confidence in our long-term strategy.”


Clinical Highlights



(1)



:

  • Same Facilities achieved Centers for Medicare & Medicaid Services (CMS) Quality Measure ratings that were 23% better than industry peers in our operating states, demonstrating superior clinical outcomes.
  • Same Facilities achieved CMS Cycle 1 survey inspection results that were 18% better than industry peers in our operating states, validating clinical excellence through regulatory oversight.
  • Over 80% of our skilled nursing operations earned a CMS Quality Measure rating of 4 or 5 stars, demonstrating our continued commitment to delivering high-quality clinical care.
  • Rehospitalization rates for Same Facilities were 15% better than the national average, supporting successful resident recovery and continuity of care.
  • Long-stay outpatient emergency department visit rates for Same Facilities were 24% better than the national average, minimizing unnecessary hospital transfers and reducing higher-cost care.
  • Administrator turnover for Same Facilities was 46% lower than our industry peers in our operating states, supporting leadership continuity and operational stability.
  • None of our 398 affiliated facilities are designated as CMS Special Focus Facilities, reflecting our ability to improve clinical performance at troubled acquisitions and consistently maintain trust from our state and federal regulators.


Quarterly Highlights:

  • GAAP diluted earnings per share for the quarter was $1.68, an increase of 16.7% over the prior year quarter, and adjusted diluted earnings per share(2) for the quarter was $1.92, an increase of 20.8% over the prior year quarter.
  • GAAP net income was $99.7 million for the quarter, an increase of 18.2% over the prior year quarter, and adjusted net income(2) was $114.3 million for the quarter, an increase of 22.5% over the prior year quarter.
  • Same Facility and Transitioning Facility occupancy for the quarter were 84.1% and 84.7%, an increase of 2.7% and 2.3%, respectively, over the prior year quarter.
  • Same Facility and Transitioning Facility skilled mix revenue for the quarter increased by 10.1% and 14.0%, respectively, and skilled days for the quarter increased by 6.2% and 9.4%, respectively, both over the prior year quarter.
  • Same Facility and Transitioning Facility Medicare revenue for the quarter improved by 9.8% and 9.6%, respectively, and Medicare days for the quarter improved by 5.1% and 5.2%, respectively, both over the prior year quarter.
  • Same Facility and Transitioning Facility managed care revenue for the quarter improved by 6.1% and 16.2%, respectively, and managed care days for the quarter improved by 1.9% and 7.6%, respectively, both over the prior year quarter.
  • Same Facility and Transitioning Facility skilled services revenue for the quarter increased by 6.6% and 6.1% over the prior year quarter.
  • Consolidated revenue for the quarter was $1.44 billion, an increase of 17.3% over the prior year quarter.
  • Standard Bearer(3) revenue was $44.1 million for the quarter, an increase of 40.2% over the prior year quarter. FFO was $24.7 million for the quarter, an increase of 34.6% over the prior year quarter.

(1)
 
The data source for clinical results is from CMS Care Compare Five-Star Quality Rating System, June 2026. Cycle 1 survey inspection results are based on the latest CMS-reported regulatory inspection cycle which reflects results as of Q4 2025. State-wide averages represent the average reported performance of facilities within the states in which we operate. National averages represent the average performance of all facilities included in the CMS Care Compare database nationwide.

(2)
 
See “Reconciliation of GAAP to Non-GAAP Financial Information”.

(3)
 
Our Skilled Services and Standard Bearer Segments are defined and outlined in Note 7 on Form 10-Q.




Clinical and Operating Results

“The strength of our model ultimately depends on the quality and stability of our people. We have long believed that outstanding resident outcomes begin with engaged, supported, and empowered caregivers. We are especially proud of our turnover. In particular, our Director of Nursing turnover continues to improve and our overall RN retention rate is also 8% better than the average across our 17-state footprint using CMS reported data. Similarly, licensed administrator turnover is an impressive 46% lower than the CMS measured state average. We believe this level of leadership stability is one of the key differentiators of our organization by creating continuity for our caregivers and residents, reinforcing accountability at the local level, and allowing the investments we make in our clinical programs, technology, and resources to translate into consistently superior quality outcomes, care efficiency, regulatory performance, and financial results.”

He added, “On the census front, our Same Facility and Transitioning Facility occupancy for the second quarter was 84.1% and 84.7%, respectively. On the skilled mix front, our Same Facilities and Transitioning Facilities skilled revenue increased by 10.1% and 14.0%, respectively, over the prior year quarter. Medicare revenue increased for both our Same Facilities and Transitioning Facilities by 9.8% and 9.6%, respectively. Also, managed care revenue increased by 6.1% and 16.2%, respectively, for Same-Facilities and Transitioning Facilities over the prior year quarter, with total skilled mix days up 6.2% and 9.4%, respectively, from the prior year quarter. The primary driver of these improvements continues to be the expanding trust from the communities we serve—earned through consistent, high-quality clinical outcomes,” Port said.

“Due to the strength of the second quarter, we are increasing our annual 2026 earnings guidance to $7.75 to $7.85 per diluted share, up from our previously increased guidance of $7.48 to $7.62. We are also increasing annual revenue guidance to $5.87 billion to $5.92 billion, up from $5.81 billion to $5.86 billion. The midpoint of our earnings guidance represents an 18.7% increase over 2025 and 41.8% over 2024,” Port said.

Speaking to the Company’s acquisition growth, Chad Keetch, Ensign’s Chief Investment Officer and Executive Vice President said, “In addition, we continue to acquire new operations with significant long-term upside and expect to maintain a healthy pace of growth as we expand our mission driven approach to transform and dignify post-acute care. During the quarter and since we accelerated our growth by adding 20 new operations, all of which included real estate assets. Since 2024, we have successfully sourced, underwritten, closed, and transitioned 102 new operations across several markets, many of which are already performing at or above expectations, both clinically and financially. We continue to see opportunities that include everything from larger portfolios, landlords looking to replace current tenants, non-profits looking to divest of their post-acute assets and a steady flow of traditional one-sie two-sies. We have several new additions lining up for the second half of 2026 as our local leadership and their deal partners at the Service Center work together to source, underwrite and carefully select the right opportunities.”

Suzanne Snapper, Ensign’s Executive Vice President and Chief Financial Officer reported that the Company’s liquidity remains strong with approximately $262.3 million of cash on hand and $591.6 million of available capacity under its line-of-credit. Ms. Snapper also indicated that, “Management’s annual guidance is based on diluted weighted average common shares outstanding of approximately 59.5 million and a 25.0% tax rate. In addition, the guidance assumes, among other things, normalized insurance costs, acquisitions expected to close through the third quarter of 2026 and management’s current expectations regarding reimbursement rates. It also excludes certain charges that arise outside the normal course of business, amortization of system implementation costs, acquisition related costs and share-based compensation.”

A discussion of the Company’s use of non-GAAP financial measures is set forth below. A reconciliation of net income to adjusted EBT, EBITDA, adjusted EBITDAR, adjusted EBITDA and FFO for Standard Bearer, as well as a reconciliation of GAAP earnings per share, net income to adjusted net income and adjusted net earnings per share appear in the financial data portion of this release. More complete information is contained in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, which is expected to be filed with the SEC today and can be viewed on the Company’s website at http://www.ensigngroup.net.


Growth and Real Estate Highlights

Mr. Keetch added additional commentary on the Company’s continued acquisition activity. “We were thrilled to complete these acquisitions, and to expand our presence in Texas. These assets are made up of newly constructed, high-quality facilities in populated and growing metro-areas. However, occupancies in these operations are almost all lower than our existing operations’ average for these geographies, and all present significant clinical and operational hurdles. These operations will take some time to establish a culture of ownership and accountability, but we are encouraged with the progress we have already seen and look forward to these new additions becoming the facility of choice in the markets they serve,” Keetch said.

Standard Bearer announced the following real estate acquisitions, which are operated by an Ensign-affiliate:

  • Willow Park Rehabilitation and Care Center, a 125-bed skilled nursing facility located in Willow Park, Texas;
  • Southern Oaks Therapy and Living Center, a 150-bed skilled nursing facility located in Dallas, Texas;
  • Country Village Care / Country Village Senior Living, a healthcare campus with 136 skilled nursing beds, 38 assisted living units, and 32 memory care beds located in Angleton, Texas;
  • River Hills Health and Rehabilitation Center, a 150-bed skilled nursing facility located in Kerrville, Texas;
  • Willow Creek Lodge, a 135-bed skilled nursing facility located in Tomball, Texas;
  • Eagle Crest Rapid Recovery, a 125-bed skilled nursing facility located in Houston, Texas;
  • Falcon Point Post Acute, a 130-bed skilled nursing facility located in Katy, Texas;
  • Parks Health Center / Parks Assisted Living Center, a healthcare campus with 90 skilled nursing beds, 30 assisted living units, and 55 independent living units located in Odessa, Texas;
  • La Dora Nursing and Rehabilitation Center, a 62-bed skilled nursing facility located in Bedford, Texas;
  • River Bend Healthcare, a 115-bed skilled nursing facility located in Seguin, Texas;
  • Mustang Park Therapy and Living Center, 120-bed skilled nursing facility located in Carrollton, Texas;
  • Hilltop Village Nursing and Rehabilitation Center, 150-bed skilled nursing facility located in Kerrville, Texas;
  • Mallard Creek Therapy and living Center, 120-bed skilled nursing facility located in Fort Worth, Texas;
  • Harbor Valley Health and Rehabilitation, 120-bed skilled nursing facility located in San Antonio, Texas;
  • TruCare Living Centers – Columbus, 104-bed skilled nursing facility located in Columbus, Texas;
  • TruCare Living Centers – Palestine, 120-bed skilled nursing facility located in Palestine, Texas;
  • TruCare Living Centers – Selma, 128-bed skilled nursing facility located in Selma, Texas;
  • Woodland Health and Rehabilitation Care Center, 62-bed skilled nursing facility located in Mount Pleasant, Iowa;
  • Las Ventanas de Socorro, a 126-bed skilled nursing facility located in Socorro, Texas; and
  • Los Arcos del Norte Care Center, a 124-bed skilled nursing facility located in El Paso, Texas.

Ensign’s growing portfolio consists of 398 healthcare operations, 32 of which also include senior living operations, across 17 states. Ensign now owns 183 real estate assets, 144 of which are operated by an Ensign affiliate. Mr. Keetch noted that Ensign’s overall strategy will continue to include both leasing and acquiring real estate, and the Company is actively looking for performing and underperforming operations in several states.

In addition, the Company also acquired three senior living real estate assets that are operated by a third-party under a triple net lease:

  • Emerald Ridge of Neenah, a 45-unit residential care apartment complex located in Neenah, Wisconsin;
  • Anna’s House Assisted Living, a 50-unit community based residential facility located in New Franken, Wisconsin; and
  • Memory Care of Contra Costa, a 46-unit memory care facility located in Pleasant Hill, California.

The Company continues to provide additional disclosure on Standard Bearer which is comprised of 177 owned properties. Of these assets, 140 are leased to an Ensign-affiliated operator and 38 are leased to third-party operators. Mr. Keetch noted that each of these properties are subject to triple-net, long-term leases and generated rental revenue of $44.1 million for the quarter, of which $37.8 million was derived from Ensign affiliated operations. For the quarter, Ensign reported $24.7 million in FFO.

The Company also paid a quarterly cash dividend of $0.065 per share of Ensign common stock. Ms. Snapper noted that as the Company’s liquidity remains strong, it plans to continue its long history of paying dividends into the future.


Conference Call

A live webcast will be held Wednesday, July 29, 2026, at 10:00 a.m. Pacific time (1:00 p.m. Eastern time) to discuss Ensign’s second quarter of 2026 financial results. To listen to the webcast, or to view any financial or statistical information required by SEC Regulation G, please visit the Investors Relations section of Ensign’s website at http://investor.ensigngroup.net. The webcast will be recorded and will be available for replay via the website until 5:00 p.m. Pacific time on Friday, August 28, 2026.


About Ensign™

The Ensign Group, Inc.’s independent subsidiaries provide a broad spectrum of skilled nursing and senior living services, physical, occupational and speech therapies and other rehabilitative and healthcare services at 398 healthcare facilities in Alabama, Alaska, Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, Oregon, South Carolina, Tennessee, Texas, Utah, Washington and Wisconsin. As part of its investment strategy, the Company will also acquire, lease and own healthcare real estate to service the post-acute care continuum through acquisition and investment opportunities in healthcare properties. Ensign’s new business venture operating subsidiaries also offer several other post-acute-related services, including mobile x-ray, emergency and non-emergency transportation services, long-term care pharmacy and other consulting services also across several states. Each of these operations is operated by a separate, independent subsidiary that has its own management, employees and assets. References herein to the consolidated “Company” and “its” assets and activities, as well as the use of the terms “we,” “us,” “its” and similar verbiage, are not meant to imply that The Ensign Group, Inc. has direct operating assets, employees or revenue, or that any of the facilities, the Service Center, Standard Bearer or the captive insurance subsidiary are operated by the same entity. More information about Ensign is available at http://www.ensigngroup.net


Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This press release contains, and the related conference call and webcast will include forward-looking statements that are based on management’s current expectations, assumptions and beliefs about its business, financial performance, operating results, the industry in which it operates and other future events. Forward-looking statements can often be identified by words such as “anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” “would,” “could,” “potential,” “continue,” “ongoing,” similar expressions, and variations or negatives of these words. These forward-looking statements include, but are not limited to, statements regarding growth prospects, future operating and financial performance, and acquisition activities. They are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to materially and adversely differ from those expressed in any forward-looking statement.

These risks and uncertainties relate to the Company’s business, its industry and its common stock and include: reduced prices and reimbursement rates for its services; its ability to acquire, develop, manage or improve operations, its ability to manage its increasing borrowing costs as it incurs additional indebtedness to fund the acquisition and development of operations; its ability to access capital on a cost-effective basis to continue to successfully implement its growth strategy; its operating margins and profitability could suffer if it is unable to grow and manage effectively its increasing number of operations; competition from other companies in the acquisition, development and operation of facilities; its ability to defend claims and lawsuits, including professional liability claims alleging that our services resulted in personal injury, and other regulatory-related claims; and the application of existing or proposed government regulations, or the adoption of new laws and regulations, that could limit its business operations, require it to incur significant expenditures or limit its ability to relocate its operations if necessary. Additionally, our business and operations continue to be impacted by the unprecedented nature of the changes in the regulations and environment, as such, we are unable to predict the full extent and duration of the financial impact of these changes on our business, financial condition and results of operations. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors. Readers should not place undue reliance on any forward-looking statements and are encouraged to review the Company’s periodic filings with the Securities and Exchange Commission, including its Form 10-Q and 10-K, for a more complete discussion of the risks and other factors that could affect Ensign’s business, prospects and any forward-looking statements. Except as required by the federal securities laws, Ensign does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changing circumstances or any other reason after the date of this press release.


Contact Information


Investor/Media Relations, The Ensign Group, Inc., (949) 487-9500, [email protected]
SOURCE: The Ensign Group, Inc.

THE ENSIGN GROUP, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME
  Three Months Ended June 30,   Six Months Ended June 30,
    2026       2025       2026       2025  
               
  (In thousands, except per share data)
REVENUE              
Service revenue $ 1,432,497     $ 1,221,414     $ 2,814,800     $ 2,388,454  
Rental revenue   7,984       6,355       14,877       12,356  
TOTAL REVENUE $ 1,440,481     $ 1,227,769     $ 2,829,677     $ 2,400,810  
Expense:              
Cost of services   1,134,237       971,780       2,230,063       1,899,629  
Rent—cost of services   66,412       57,195       131,918       114,271  
General and administrative expense   85,922       69,107       160,132       131,662  
Depreciation and amortization   31,406       25,785       60,207       49,973  
TOTAL EXPENSES $ 1,317,977     $ 1,123,867     $ 2,582,320     $ 2,195,535  
Income from operations   122,504       103,902       247,357       205,275  
Other income (expense):              
Interest expense   (1,933 )     (2,025 )     (3,865 )     (4,062 )
Interest income   4,633       5,240       11,169       12,123  
Other income   8,470       5,241       7,585       5,602  
OTHER INCOME, NET $ 11,170     $ 8,456     $ 14,889     $ 13,663  
Income before provision for income taxes   133,674       112,358       262,246       218,938  
Provision for income taxes   33,840       27,892       62,656       54,119  
NET INCOME $ 99,834     $ 84,466     $ 199,590     $ 164,819  
Less: net income attributable to noncontrolling interests   96       70       184       146  
NET INCOME ATTRIBUTABLE TO THE ENSIGN GROUP, INC. $ 99,738     $ 84,396     $ 199,406     $ 164,673  
               
NET INCOME PER SHARE ATTRIBUTABLE TO THE ENSIGN GROUP INC.              
Basic $ 1.72     $ 1.48     $ 3.45     $ 2.88  
Diluted $ 1.68     $ 1.44     $ 3.35     $ 2.81  
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING              
Basic   57,958       57,157       57,865       57,128  
Diluted   59,483       58,602       59,527       58,560  

THE ENSIGN GROUP, INC.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
  June 30, 2026   December 31, 2025
       
ASSETS      
Current assets:      
Cash and cash equivalents $ 262,300   $ 503,881
Accounts receivable—less allowance for doubtful accounts of $7,895 and $7,805 at June 30, 2026 and December 31, 2025, respectively   668,902     636,985
Investments—current   58,544     68,506
Prepaid expenses and other current assets   81,742     62,932
Total current assets $ 1,071,488   $ 1,272,304
Property and equipment, net   2,096,977     1,696,863
Right-of-use assets   2,143,787     2,097,862
Insurance subsidiary deposits and investments   210,077     166,841
Deferred tax assets   83,068     83,138
Restricted and other assets   39,755     41,600
Intangible assets, net   6,263     6,381
Goodwill   97,981     97,981
TOTAL ASSETS $ 5,749,396   $ 5,462,970
LIABILITIES AND EQUITY      
Current liabilities:      
Accounts payable $ 119,675   $ 97,327
Accrued wages and related liabilities   368,817     422,326
Lease liabilities—current   121,117     114,816
Accrued self-insurance liabilities—current   100,007     81,623
Other accrued liabilities   171,001     174,027
Current maturities of long-term debt   4,182     4,227
Total current liabilities $ 884,799   $ 894,346
Long-term lease liabilities—less current portion   1,989,485     1,949,213
Accrued self-insurance liabilities—less current portion   195,813     164,792
Other long-term liabilities   98,428     82,266
Long-term debt—less current maturities   135,562     137,529
Total equity   2,445,309     2,234,824
TOTAL LIABILITIES AND EQUITY $ 5,749,396   $ 5,462,970

THE ENSIGN GROUP, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
   
The following table presents selected data from our condensed consolidated statements of cash flows for the periods presented:
 
  Six Months Ended June 30,
    2026       2025  
       
NET CASH PROVIDED BY (USED IN):  
Operating activities $ 272,108     $ 227,950  
Investing activities   (478,893 )     (311,924 )
Financing activities   (34,796 )     (16,655 )
Net decrease in cash and cash equivalents $ (241,581 )   $ (100,629 )
Cash and cash equivalents beginning of period   503,881       464,598  
Cash and cash equivalents at end of period $ 262,300     $ 363,969  

THE ENSIGN GROUP, INC.

UNAUDITED RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION
(In thousands, except per share data)


RECONCILIATION OF GAAP TO NON-GAAP NET INCOME

The following table reconciles net income to Adjusted net income and diluted earnings per share to Adjusted earnings per share for the periods presented:

  Three Months Ended June 30,   Six Months Ended June 30,
    2026       2025       2026       2025  
Net income attributable to The Ensign Group, Inc. $ 99,738     $ 84,396     $ 199,406     $ 164,673  
Adjustments:              
Stock-based compensation expense(1)   16,166       11,662       30,061       22,386  
Cost of services – loss (gain) on long-lived assets and business interruption recoveries         (1,000 )     1,284       (1,000 )
Cost of services – acquisition related costs(2)   519       654       800       1,135  
General and administrative – costs incurred related to system implementations   2,180       437       5,199       771  
Depreciation and amortization – patient base(3)         409             1,020  
Provision for income taxes on Non-GAAP adjustments(4)   (4,295 )     (3,238 )     (12,242 )     (6,693 )
Adjusted Net Income $ 114,308     $ 93,320     $ 224,508     $ 182,292  
               
Average number of diluted shares outstanding   59,483       58,602       59,527       58,560  
               
Diluted Earnings Per Share $ 1.68     $ 1.44     $ 3.35     $ 2.81  
               
Adjusted Earnings Per Share $ 1.92     $ 1.59     $ 3.77     $ 3.11  
               
Footnotes:              
(1) Represents stock-based compensation expense incurred.        
  Three Months Ended June 30,   Six Months Ended June 30,
    2026       2025       2026       2025  
Cost of services $ 10,723     $ 7,874     $ 19,893     $ 15,033  
General and administrative   5,443       3,788       10,168       7,353  
Total Non-GAAP adjustment $ 16,166     $ 11,662     $ 30,061     $ 22,386  
               
(2) Represents costs incurred to acquire operations that are not capitalizable.
(3) Represents amortization expenses related to patient base intangible assets at newly acquired skilled nursing and senior living facilities.
(4) Represents an adjustment to the provision for income tax to our historical effective tax rate of 25.0%

THE ENSIGN GROUP, INC.

UNAUDITED RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION
(In thousands)

The table below reconciles net income to EBITDA, Adjusted EBITDA and Adjusted EBITDAR for the periods presented:

  Three Months Ended June 30,   Six Months Ended June 30,
  2026     2025       2026     2025  
Consolidated Statements of Income Data:              
Net income $ 99,834   $ 84,466     $ 199,590   $ 164,819  
Less: Net income attributable to noncontrolling interests   96     70       184     146  
Interest income   4,633     5,240       11,169     12,123  
Add: Provision for income taxes   33,840     27,892       62,656     54,119  
Depreciation and amortization   31,406     25,785       60,207     49,973  
Interest expense   1,933     2,025       3,865     4,062  
EBITDA $ 162,284   $ 134,858     $ 314,965   $ 260,704  
Adjustments to EBITDA:              
Stock-based compensation expense   16,166     11,662       30,061     22,386  
Costs incurred related to system implementations   2,180     437       5,199     771  
Loss (gain) on long-lived assets and business interruption recoveries       (1,000 )     1,284     (1,000 )
Acquisition related costs(1)   519     654       800     1,135  
ADJUSTED EBITDA $ 181,149   $ 146,611     $ 352,309   $ 283,996  
Rent—cost of services   66,412     57,195       131,918     114,271  
ADJUSTED EBITDAR $ 247,561       $ 484,227    

(1) Represents costs incurred to acquire operations that are not capitalizable.

The table below reconciles income before provision for income taxes to Adjusted EBT for the periods presented:

  Three Months Ended June 30,   Six Months Ended June 30,
  2026     2025       2026     2025  
Consolidated statements of income data: (In thousands)
Income before provision for income taxes $ 133,674   $ 112,358     $ 262,246   $ 218,938  
Stock-based compensation expense   16,166     11,662       30,061     22,386  
Costs incurred related to system implementations   2,180     437       5,199     771  
Loss (gain) on long-lived assets and business interruption recoveries       (1,000 )     1,284     (1,000 )
Acquisition related costs(1)   519     654       800     1,135  
Depreciation and amortization – patient base(2)       409           1,020  
ADJUSTED EBT $ 152,539   $ 124,520     $ 299,590   $ 243,250  

(1) Represents costs incurred to acquire operations that are not capitalizable.
(2) Represents amortization expenses related to patient base intangible assets at newly acquired skilled nursing and senior living facilities.

THE ENSIGN GROUP, INC.

UNAUDITED SELECT PERFORMANCE INDICATORS

The following tables summarize our selected performance indicators for our skilled services segment along with other statistics, for each of the dates or periods presented:

  Three Months Ended June 30,
  2026
  2025
  Change   % Change
               
TOTAL FACILITY RESULTS: (Dollars in thousands)
Skilled services revenue $ 1,379,912     $ 1,173,576     $ 206,336     17.6 %
Number of facilities at period end   348       304       44     14.5 %
Number of campuses at period end(1)   32       30       2     6.7 %
Actual patient days   3,017,641       2,615,490       402,151     15.4 %
Occupancy percentage — Operational beds   82.9 %     81.3 %     1.6 %   2.0 %
Skilled mix by nursing days   31.0 %     30.8 %     0.2 %   0.6 %
Skilled mix by nursing revenue   50.0 %     49.2 %     0.8 %   1.6 %
  Three Months Ended June 30,
    2026       2025     Change   % Change
               
SAME FACILITY RESULTS:

(2)
(Dollars in thousands)
Skilled services revenue $ 988,337     $ 926,850     $ 61,487     6.6 %
Number of facilities at period end   234       234           %
Number of campuses at period end(1)   25       25           %
Actual patient days   2,164,347       2,091,332       73,015     3.5 %
Occupancy percentage — Operational beds   84.1 %     81.9 %     2.2 %   2.7 %
Skilled mix by nursing days   32.2 %     31.3 %     0.9 %   2.9 %
Skilled mix by nursing revenue   51.0 %     50.1 %     0.9 %   1.8 %
  Three Months Ended June 30,
    2026       2025     Change   % Change
               
TRANSITIONING FACILITY RESULTS:

(3)
(Dollars in thousands)
Skilled services revenue $ 197,371     $ 185,981     $ 11,390     6.1 %
Number of facilities at period end   50       50           %
Number of campuses at period end(1)   4       4           %
Actual patient days   405,468       393,063       12,405     3.2 %
Occupancy percentage — Operational beds   84.7 %     82.8 %     1.9 %   2.3 %
Skilled mix by nursing days   29.7 %     28.0 %     1.7 %   6.1 %
Skilled mix by nursing revenue   49.7 %     47.0 %     2.7 %   5.7 %
  Three Months Ended June 30,
    2026       2025     Change   % Change
               
RECENTLY ACQUIRED FACILITY RESULTS:

(4)
(Dollars in thousands)
Skilled services revenue $ 194,204     $ 60,745     $ 133,459   NM
Number of facilities at period end   64       20       44   NM
Number of campuses at period end(1)   3       1       2   NM
Actual patient days   447,826       131,095       316,731   NM
Occupancy percentage — Operational beds   76.6 %     69.9 %   NM   NM
Skilled mix by nursing days   26.9 %     30.4 %   NM   NM
Skilled mix by nursing revenue   45.1 %     43.0 %   NM   NM

(1)   Campus represents a facility that offers both skilled nursing and senior living services. Revenue and expenses related to skilled nursing and senior living services have been allocated and recorded in the respective operating segment.
(2)   Same Facility results represent all facilities acquired prior to January 1, 2023.
(3)   Transitioning Facility results represent all facilities acquired from January 1, 2023 to December 31, 2024.
(4)   Recently Acquired Facility results represent all facilities acquired on or subsequent to January 1, 2025.
  Six Months Ended June 30,
    2026       2025     Change   % Change
               
TOTAL FACILITY RESULTS: (Dollars in thousands)
Skilled services revenue $ 2,710,747     $ 2,297,130     $ 413,617     18.0 %
Number of facilities at period end   348       304       44     14.5 %
Number of campuses at period end(1)   32       30       2     6.7 %
Actual patient days   5,913,675       5,153,626       760,049     14.7 %
Occupancy percentage — Operational beds   83.4 %     81.6 %     1.8 %   2.2 %
Skilled mix by nursing days   31.5 %     31.1 %     0.4 %   1.3 %
Skilled mix by nursing revenue   50.3 %     49.7 %     0.6 %   1.2 %
  Six Months Ended June 30,
    2026       2025     Change   % Change
               
SAME FACILITY RESULTS:

(2)
(Dollars in thousands)
Skilled services revenue $ 1,967,545     $ 1,843,338     $ 124,207     6.7 %
Number of facilities at period end   234       234           %
Number of campuses at period end(1)   25       25           %
Actual patient days   4,309,728       4,170,184       139,544     3.3 %
Occupancy percentage — Operational beds   84.2 %     82.1 %     2.1 %   2.6 %
Skilled mix by nursing days   32.4 %     31.8 %     0.6 %   1.9 %
Skilled mix by nursing revenue   51.1 %     50.6 %     0.5 %   1.0 %
  Six Months Ended June 30,
    2026       2025     Change   % Change
               
TRANSITIONING FACILITY RESULTS:

(3)
(Dollars in thousands)
Skilled services revenue $ 392,857     $ 364,903     $ 27,954     7.7 %
Number of facilities at period end   50       50           %
Number of campuses at period end(1)   4       4           %
Actual patient days   807,732       778,169       29,563     3.8 %
Occupancy percentage — Operational beds   84.9 %     82.4 %     2.5 %   3.0 %
Skilled mix by nursing days   29.9 %     28.4 %     1.5 %   5.3 %
Skilled mix by nursing revenue   49.7 %     47.6 %     2.1 %   4.4 %
  Six Months Ended June 30,
    2026       2025     Change   % Change
               
RECENTLY ACQUIRED FACILITY RESULTS:

(4)
(Dollars in thousands)
Skilled services revenue $ 350,345     $ 88,889     $ 261,456   NM
Number of facilities at period end   64       20       44   NM
Number of campuses at period end(1)   3       1       2   NM
Actual patient days   796,215       205,273       590,942   NM
Occupancy percentage — Operational beds   78.3 %     70.0 %   NM   NM
Skilled mix by nursing days   28.5 %     27.7 %   NM   NM
Skilled mix by nursing revenue   46.8 %     39.9 %   NM   NM
  1. Campus represents a facility that offers both skilled nursing and senior living services. Revenue and expenses related to skilled nursing and senior living services have been allocated and recorded in the respective operating segment.
  2. Same Facility results represent all facilities acquired prior to January 1, 2023.
  3. Transitioning Facility results represent all facilities acquired from January 1, 2023 to December 31, 2024.
  4. Recently Acquired Facility results represent all facilities acquired on or subsequent to January 1, 2025.

THE ENSIGN GROUP, INC.

UNAUDITED SKILLED NURSING AVERAGE DAILY REVENUE RATES AND
PERCENT OF SKILLED NURSING REVENUE AND DAYS BY PAYOR

The following tables reflect the change in skilled nursing average daily revenue rates, excluding services that are not covered by the daily rate(1):

  Three Months Ended June 30,
  Same Facility   Transitioning   Acquisitions   Total
  2026   2025   2026   2025   2026   2025   2026   2025
SKILLED NURSING AVERAGE DAILY REVENUE RATES
Medicare $ 814.66   $ 779.77   $ 890.48   $ 854.83   $ 784.73   $ 701.40   $ 822.24   $ 789.43
Managed care   599.06     575.29     658.87     609.88     630.25     555.77     609.07     578.40
Other skilled   649.37     647.61     678.38     685.81     683.77     711.96     655.51     655.04
Total skilled revenue   685.04     661.18     776.70     745.39     713.52     652.03     700.39     672.15
Medicaid   310.64     302.36     326.89     321.75     316.83     374.44     313.78     308.87
Private and other payors   317.27     288.43     362.96     357.18     330.50     392.10     326.20     305.96
Total skilled nursing revenue $ 431.71   $ 413.41   $ 464.31   $ 444.50   $ 425.26   $ 460.83   $ 435.10   $ 420.43

  Six Months Ended June 30,
  Same Facility   Transitioning   Acquisitions   Total
  2026   2025   2026   2025
  2026   2025   2026   2025
SKILLED NURSING AVERAGE DAILY REVENUE RATES
Medicare $ 812.17   $ 777.70   $ 885.86   $ 848.13   $ 796.67   $ 667.40   $ 822.04   $ 786.58
Managed care   594.97     570.02     652.52     605.80     627.83     522.15     604.67     572.51
Other skilled   646.93     645.85     680.76     668.45     659.88     714.24     651.51     650.67
Total skilled revenue   682.14     657.16     773.10     739.60     714.40     621.17     697.78     667.17
Medicaid   311.49     299.67     328.56     316.93     318.27     356.51     314.77     304.65
Private and other payors   314.74     289.10     365.97     354.74     348.25     364.34     327.66     303.52
Total skilled nursing revenue $ 431.75   $ 412.14   $ 465.42   $ 441.17   $ 434.75   $ 430.70   $ 436.73   $ 417.23

(1) The rates are based on contractually agreed-upon amounts or rates, excluding the estimates of variable consideration under the revenue recognition standard, Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606.

The following tables set forth our percentage of skilled nursing patient revenue and days for the periods presented:

  Three Months Ended June 30,
  Same Facility   Transitioning   Acquisitions   Total
  2026
  2025
  2026
  2025
  2026
  2025
  2026
  2025
                               
PERCENTAGE OF SKILLED NURSING REVENUE
Medicare 21.2 %   20.9 %   28.3 %   27.8 %   24.1 %   19.1 %   22.6 %   21.9 %
Managed care 19.6     19.9     15.1     14.0     14.4     13.0     18.2     18.6  
Other skilled 10.2     9.3     6.3     5.2     6.6     10.9     9.2     8.7  
Skilled mix 51.0 %   50.1 %   49.7 %   47.0 %   45.1 %   43.0 %   50.0 %   49.2 %
Private and other payors 7.1     6.9     8.4     9.2     10.6     10.0     7.7     7.5  
Medicaid 41.9     43.0     41.9     43.8     44.3     47.0     42.3     43.3  
TOTAL SKILLED NURSING 100.0 %   100.0 %   100.0 %   100.0 %   100.0 %   100.0 %   100.0 %   100.0 %
  Three Months Ended June 30,
  Same Facility   Transitioning   Acquisitions   Total
  2026
  2025
  2026
  2025
  2026
  2025
  2026
  2025
                               
PERCENTAGE OF SKILLED NURSING DAYS
Medicare 11.2 %   11.1 %   14.7 %   14.5 %   13.1 %   12.6 %   12.0 %   11.6 %
Managed care 14.1     14.3     10.6     10.2     9.7     10.8     13.0     13.5  
Other skilled 6.9     5.9     4.4     3.3     4.1     7.0     6.0     5.7  
Skilled mix 32.2 %   31.3 %   29.7 %   28.0 %   26.9 %   30.4 %   31.0 %   30.8 %
Private and other payors 9.6     9.9     10.7     11.5     13.7     11.8     10.4     10.2  
Medicaid 58.2     58.8     59.6     60.5     59.4     57.8     58.6     59.0  
TOTAL SKILLED NURSING 100.0 %   100.0 %   100.0 %   100.0 %   100.0 %   100.0 %   100.0 %   100.0 %
  Six Months Ended June 30,
  Same Facility   Transitioning   Acquisitions   Total
  2026
  2025
  2026
  2025
  2026
  2025
  2026
  2025
                               
PERCENTAGE OF SKILLED NURSING REVENUE
Medicare 21.4 %   21.1 %   28.4 %   28.4 %   25.2 %   18.2 %   23.0 %   22.2 %
Managed care 19.7     20.4     14.9     14.0     14.9     12.8     18.4     19.1  
Other skilled 10.0     9.1     6.4     5.2     6.7     8.9     8.9     8.4  
Skilled mix 51.1 %   50.6 %   49.7 %   47.6 %   46.8 %   39.9 %   50.3 %   49.7 %
Private and other payors 7.0     6.9     8.3     9.0     9.9     10.3     7.6     7.4  
Medicaid 41.9     42.5     42.0     43.4     43.3     49.8     42.1     42.9  
TOTAL SKILLED NURSING 100.0 %   100.0 %   100.0 %   100.0 %   100.0 %   100.0 %   100.0 %   100.0 %
  Six Months Ended June 30,
  Same Facility   Transitioning   Acquisitions   Total
  2026
  2025
  2026
  2025
  2026
  2025
  2026
  2025
                               
PERCENTAGE OF SKILLED NURSING DAYS
Medicare 11.4 %   11.2 %   14.9 %   14.8 %   13.8 %   11.8 %   12.2 %   11.8 %
Managed care 14.3     14.7     10.6     10.2     10.4     10.5     13.3     13.9  
Other skilled 6.7     5.9     4.4     3.4     4.3     5.4     6.0     5.4  
Skilled mix 32.4 %   31.8 %   29.9 %   28.4 %   28.5 %   27.7 %   31.5 %   31.1 %
Private and other payors 9.5     9.8     10.6     11.2     12.4     12.2     10.0     10.1  
Medicaid 58.1     58.4     59.5     60.4     59.1     60.1     58.5     58.8  
TOTAL SKILLED NURSING 100.0 %   100.0 %   100.0 %   100.0 %   100.0 %   100.0 %   100.0 %   100.0 %

THE ENSIGN GROUP, INC.

UNAUDITED REVENUE BY PAYOR SOURCE

The following tables set forth our service revenue by payor source and as a percentage of total service revenue for the periods presented:

  Three Months Ended June 30,
    2026       2025  
  Revenue   % of Revenue   Revenue   % of Revenue
Medicaid(1) $ 566,819   39.6 %   $ 485,848   39.8 %
Medicare   339,650   23.7       291,117   23.8  
Medicaid-skilled   80,664   5.6       75,207   6.2  
Total Medicaid and Medicare $ 987,133   68.9 %   $ 852,172   69.8 %
Managed care   265,348   18.5       229,495   18.8  
Private and other(2)   180,016   12.6       139,747   11.4  
SERVICE REVENUE $ 1,432,497   100.0 %   $ 1,221,414   100.0 %

(1) Medicaid payor includes revenue for senior living operations.
(2) Private and other includes revenue for skilled services (private, Veteran Affairs and hospice payors), senior living and ancillary operations.

  Six Months Ended June 30,
    2026       2025  
  Revenue   % of Revenue   Revenue   % of Revenue
Medicaid(1) $ 1,110,269   39.4 %   $ 939,688   39.3 %
Medicare   675,479   24.0       578,868   24.2  
Medicaid-skilled   155,902   5.6       144,758   6.1  
Total Medicaid and Medicare $ 1,941,650   69.0 %   $ 1,663,314   69.6 %
Managed care   526,199   18.7       456,712   19.1  
Private and other(2)   346,951   12.3       268,428   11.3  
SERVICE REVENUE $ 2,814,800   100.0 %   $ 2,388,454   100.0 %

(1) Medicaid payor includes revenue for senior living operations.
(2) Private and other includes revenue for skilled services (private, Veteran Affairs and hospice payors), senior living and ancillary operations.

THE ENSIGN GROUP, INC.

UNAUDITED RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION BY SEGMENT
(In thousands)


Skilled Services

The table below reconciles net income to EBITDA and Adjusted EBITDA for the skilled services reportable segment for the periods presented:

  Three Months Ended June 30,   Six Months Ended June 30,
  2026     2025     2026     2025  
Statements of Income Data:              
Segment income(1) $ 179,621   $ 150,004     $ 353,638   $ 293,935  
Depreciation and amortization   15,445     13,750       30,755     26,963  
EBITDA $ 195,066   $ 163,754     $ 384,393   $ 320,898  
Adjustments to EBITDA:              
Stock-based compensation expense   10,285     7,567       19,036     14,447  
Gain on business interruption recoveries       (1,000 )         (1,000 )
ADJUSTED EBITDA $ 205,351   $ 170,321     $ 403,429   $ 334,345  

(1) Segment income reflects profit from operations before provision for income taxes and impairment charges from operations. General and administrative expenses are not allocated to the skilled services segment for purposes of determining segment profit or loss.


Standard Bearer

The following table sets forth details of operating results for our revenue and earnings, and their respective components, by Standard Bearer for the periods presented:

  Three Months Ended June 30,   Six Months Ended June 30,
    2026     2025     2026     2025
Rental revenue generated from third-party tenants $ 6,348   $ 4,712   $ 11,618   $ 9,209
Rental revenue generated from Ensign’s independent subsidiaries   37,785     26,756     68,617     50,660
TOTAL RENTAL REVENUE $ 44,133   $ 31,468   $ 80,235   $ 59,869
Segment income(1)   12,070     9,126     22,879     17,709
Depreciation and amortization   12,676     9,265     23,459     17,741
FFO

(2)
$ 24,746   $ 18,391   $ 46,338   $ 35,450

(1) Segment income reflects profit from operations before provision for income taxes, excluding gain or loss from sale of real estate, insurance recoveries and impairment of long-lived assets. Included in Standard Bearer expenses for the three and six months ended June 30, 2026 is management fee of $2.6 million and $4.8 million, respectively, and interest of $14.1 million and $23.9 million, respectively, from intercompany agreements between Standard Bearer and the Company and its independent subsidiaries, including the Service Center. Included in Standard Bearer expenses for the three and six months ended June 30, 2025 is management fee of $1.9 million and $3.6 million, respectively, and interest of $9.0 million and $16.1 million, respectively, from intercompany agreements between Standard Bearer and the Company and its independent subsidiaries, including the Service Center.

(2) FFO, in accordance with the definition used by the National Association of Real Estate Investment Trusts, means net income attributable to common stockholders, computed in accordance with U.S. GAAP, excluding gains or losses from sale of real estate, insurance recoveries related to real estate and impairment of long-lived assets, while including depreciation and amortization related to real estate to earnings.


Discussion of Non-GAAP Financial Measures

Adjusted EBT consists of net income before (a) provision for income taxes, (b) stock-based compensation expense, (c) acquisition related costs, (d) costs incurred related to system implementations, (e) loss (gain) on long-lived assets and business interruption recoveries, and (g) amortization of patient base intangible assets. Adjusted net income consists of net income excluding (a) stock‑based compensation expense, (b) acquisition related costs, (c) costs incurred related to system implementations, (d) loss (gain) on long-lived assets and business interruption recoveries, (e) amortization of patient base intangible assets and (f) the income tax effect of these adjustments. Adjusted earnings per share consists of adjusted net income divided by the weighted‑average diluted shares outstanding for the applicable period. EBITDA consists of net income before (a) interest income, (b) provision for income taxes, (c) depreciation and amortization and (d) interest expense. Adjusted EBITDA consists of net income before (a) interest income, (b) provision for income taxes, (c) depreciation and amortization, (d) interest expense, (e) stock-based compensation expense, (f) acquisition related costs, (g) costs incurred related to system implementations, and (h) loss (gain) on long-lived assets and business interruption recoveries. Adjusted EBITDAR consists of net income before (a) interest income, (b) provision for income taxes, (c) depreciation and amortization, (d) interest expense, (e) rent-cost of services, (f) stock-based compensation expense, (g) acquisition related costs, (h) costs incurred related to system implementations, and (i) loss (gain) on long-lived assets and business interruption recoveries. Funds from Operations (FFO) for our Standard Bearer segment consists of segment income, excluding depreciation and amortization related to real estate, gains or losses from the sale of real estate, insurance recoveries related to real estate and impairment of long-lived assets. The Company believes that the presentation of adjusted EBT, adjusted net income, adjusted earnings per share, EBITDA, adjusted EBITDA and FFO provides important supplemental information to management and investors to evaluate the Company’s operating performance. Adjusted EBITDAR is a financial valuation measure that is not specified in GAAP. This measure is not displayed as a performance measure as it excludes rent expense, which is a normal and recurring operating expense. The Company believes disclosure of adjusted EBT, adjusted net income, adjusted net income per share, EBITDA, adjusted EBITDA, adjusted EBITDAR and FFO has substance because the excluded revenues and expenses are infrequent in nature and are variable in nature, or do not represent current revenues or cash expenditures. A material limitation associated with the use of these measures as compared to the GAAP measures of net income and diluted earnings per share is that they may not be comparable with the calculation of net income and diluted earnings per share for other companies in the Company’s industry. These non-GAAP financial measures should not be relied upon to the exclusion of GAAP financial measures. For further information regarding why the Company believes that this non-GAAP measures provide useful information to investors, the specific manner in which management uses these measures, and some of the limitations associated with the use of these measures, please refer to the Company’s periodic filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and Quarterly Report on Form 10-Q. The Company’s periodic filings are available on the SEC’s website at www.sec.gov or under the “Financials” link of the Investor Relations section on Ensign’s website at http://www.ensigngroup.net



Lifezone Announces Release Date of H1 2026 Interim Financial Results and Notice of Investor Webcast

Lifezone Announces Release Date of H1 2026 Interim Financial Results and Notice of Investor Webcast

NEW YORK–(BUSINESS WIRE)–
Lifezone Metals Limited (NYSE: LZM) announced today that it plans to release its H1 2026 interim financial results on July 29, 2026.

Investor Webcast: July 29, 2026 / 10:00 a.m. ET | 15:00 p.m. BST

Chris Showalter, CEO and Ingo Hofmaier, CFO, will be hosting a conference call and Q&A on the day. Analysts and investors can register at: Lifezone Metals H1 2026 Interim Financial Results Webcast.

If you would like to sign up for Lifezone Metals news alerts, please register here.

Social Media

LinkedIn | X | YouTube

About Lifezone Metals

Lifezone Metals (NYSE: LZM) is committed to delivering cleaner and more responsible metals production and recycling. Through the application of our Hydromet Technology, we offer the potential for lower energy consumption, lower emissions and lower cost metals production compared to traditional smelting.

Our Kabanga Nickel Project in Tanzania is believed to be one of the world’s largest and highest-grade development-ready nickel sulfide deposits. By pairing it with our Hydromet Technology, we are working to unlock a new source of nickel, copper and cobalt for the global battery metals markets and to empower Tanzania to achieve in-country beneficiation.

Through our US-based recycling partnership, we are working towards applying our Hydromet Technology to the recovery of platinum, palladium and rhodium from responsibly sourced spent automotive catalytic converters. Our process is expected to be cleaner and more efficient than conventional smelting and refining methods, supporting a circular economy for precious metals.

https://lifezonemetals.com

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the “safe harbor” provisions under the Private Securities Litigation Reform Act of 1995. Generally, statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies, events or results of operations, and any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Forward-looking statements may be accompanied by words such as “believes,” “estimates,” “expects,” “predicts,” “projects,” “forecasts,” “may,” “might,” “will,” “could,” “should,” “would,” “seeks,” “plans,” “scheduled,” “possible,” “continue,” “potential,” “anticipates” or “intends” or the negatives of these terms or variations of them or similar terminology or expressions that predict or indicate future events or trends or that are not statements of historical matters; provided, however, that the absence of these words does not mean that a statement is not forward-looking.

Forward-looking statements in this press release, include, but are not limited to, statements regarding the proposed release of the H1 2026 interim financial results, and the related timing. There can be no assurance as to whether or when the release of the H1 2026 interim financial results will take place. The forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially, including market and other conditions, and risks and uncertainties that may affect the Company’s business, results of operations and financial condition and future operations, and other risks that are and will be detailed from time to time in the Company’s filings with the Securities and Exchange Commission (the “Commission”), including the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2025 and the Reports on Form 6-K that the Company files and furnishes from time to time with the Commission. Further, the forward-looking statements in this press release are based on the current expectations of Lifezone Metals’ management. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Lifezone Metals and its subsidiaries. Except as otherwise required by applicable law, we disclaim any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data, or methods, future events, or other changes after the date of this communication.

Investor Relations

Ingo Hofmaier

Chief Financial Officer

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Machine Tools, Metalworking & Metallurgy Recycling Mining/Minerals Environment Manufacturing Natural Resources

MEDIA:

Logo
Logo

Allot to Release Second Quarter 2026 Results and Host Conference Call on August 12, 2026

Hod Hasharon, Israel, July 27, 2026 (GLOBE NEWSWIRE) — Allot Ltd. (NASDAQ: ALLT, TASE: ALLT), a leading global provider of innovative Security-as-a-Service (SECaaS) and network intelligence solutions for communications service providers and enterprises, announced today that it will host a conference call to discuss its second quarter 2026 results on Wednesday, August 12, 2026 at 8:30AM ET (1:30PM UK, 3:30PM Israel).

The unaudited financial results of the quarter will be published prior to the commencement of the conference call.‎

To access the conference call, please dial one of the following numbers:

US: 1-888-668-9141, UK: 0-800-917-5108, Israel: +972-3-918-0644

A live webcast of the conference call can be accessed on the Allot website at https://investors.allot.com/. The webcast will also be archived on the website following the conference call.


About Allot

Allot Ltd. (NASDAQ: ALLT, TASE: ALLT) is a leading provider of innovative converged cybersecurity solutions and network intelligence offerings for service providers and enterprises worldwide. Allot enhances value to its customers’ customers through its solutions, which are deployed globally for network-native cybersecurity services, network and application analytics, traffic control and shaping, and more. Allot’s multi-service platforms are deployed by over 500 mobile, fixed and cloud service providers and over 1000 enterprises. Our industry-leading network-native security-as-a-service solution is already used by many millions of subscribers globally.

For more information, visit www.allot.com



Investor Relations Contact:
EK Global Investor Relations
Ehud Helft
+1 212 378 8040
[email protected] 

Public Relations Contact:
Allot Ltd.
Seth Greenberg
+972 54 922 2294
[email protected] 

Rocket Lab Awarded Record $266M Missile Defense Contract with U.S. Space Force for Suborbital Launches

LONG BEACH, Calif., July 27, 2026 (GLOBE NEWSWIRE) — Rocket Lab Corporation (Nasdaq: RKLB), a global leader in launch services and space systems today announced it has been awarded its largest launch contract to date, a $266 million multi-launch contract with the U.S. Space Force. This landmark contract further solidifies Rocket Lab’s position as a leader in launch and critical mission enabler for programs with significant national importance.

Under the contract awarded by the U.S. Space Force Space Systems Command’s Rocket Systems Launch Program (RSLP), Rocket Lab will execute 12 suborbital launches, with up to six additional launches. The first launch of this contract is expected to take place no earlier than the end of 2026.

The launches will primarily take place from a new Rocket Lab location at the Pacific Spaceport Complex-Alaska (PSCA) in Kodiak, Alaska, complementing Rocket Lab’s existing launch sites at Launch Complex 1 in New Zealand, and Launch Complex 2 and Launch Complex 3 in Virginia.

Sir Peter Beck, founder and CEO of Rocket Lab, says: “Cadence, iteration, and relentless execution are essential to maturing America’s missile defense capabilities, and that’s exactly what we bring with launch leadership. The size and scale of this contract reflects the Space Force’s confidence in our ability to meet their urgent national security demands with speed, responsiveness, and scale, and we’re proud to provide the high-frequency launch capacity required to keep the U.S. ahead of global threats.”

Rocket Lab Media Contact

Murielle Baker
[email protected]

About Rocket Lab

Rocket Lab is a leading space company that provides launch services, spacecraft, payloads and satellite components serving commercial, government, and national security markets. Rocket Lab’s Electron rocket is the world’s most frequently launched orbital small rocket; its HASTE rocket provides hypersonic test launch capability for the U.S. government and allied nations; and its Neutron launch vehicle in development will unlock medium launch for constellation deployment, national security and exploration missions. Rocket Lab’s spacecraft and satellite components have enabled more than 1,700 missions spanning commercial, defense and national security missions including GPS, constellations, and exploration missions to the Moon, Mars, and Venus. Rocket Lab is a publicly listed company on the Nasdaq stock exchange (RKLB). Learn more at www.rocketlabcorp.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding our launch and space systems operations, launch schedule and window, safe and repeatable access to space, Neutron development, operational expansion and business strategy, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “potential,” “continue,” “anticipate,” “intend,” “expect,” “strategy,” “future,” “could,” “would,” “project,” “plan,” “target,” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to the factors, risks and uncertainties included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as such factors may be updated from time to time in our other filings with the Securities and Exchange Commission (the “SEC”), accessible on the SEC’s website at www.sec.gov and the Investor Relations section of our website at https://investors.rocketlabcorp.com which could cause our actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.



Profusa Announces Key Management Changes and Signing of Non-Binding Term Sheet for the Acquisition of a Commercial Stage Diagnostics Company

BERKELEY, Calif., July 27, 2026 (GLOBE NEWSWIRE) —  Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, announces the signing of a non-binding term sheet with a privately held, commercial-stage health diagnostics and toxicology testing company (the “Dx Company”). Following the contemplated transaction, the combined company is expected to operate as a public diagnostics company with national CLIA-certified laboratories, recurring revenues from a diversified base of providers serving addiction treatment, pain management, and behavioral health. The Dx Company’s 2025 Net Revenues are estimated, based on unaudited management information, to be approximately $111 million.

Mr. Jack Stover, a director of Profusa, has been appointed by the Profusa Board of Directors as Executive Chairman of the Board of Directors and Chief Executive Officer. Ben Hwang, PhD, formerly the Chief Executive Officer, Chairman, and Director of the Board of Profusa, has transitioned into the role of President of Profusa. Liviu Goldenberg has been appointed by the Profusa Board of Directors as an independent director. Mr. Goldenberg has 30+ years of global leadership experience overseeing complex operations, technology adoption, and enterprise transformation. He has deep expertise in technology-enabled manufacturing, AI / IIoT platforms, sustainability, capital deployment, and risk oversight. Mr. Goldenberg is also an active advisor to growth-stage and scale-up technology companies, with experience supporting capital raises, strategic partnerships, and institutional initiatives and importantly brings disciplined governance judgment, independence, and a long-term shareholder focus.

It is anticipated that upon the execution of a definitive acquisition agreement (the “Acquisition Agreement”), Profusa will issue to the Dx Company stockholders the following consideration: (i) shares of Profusa common stock equal to 19.99% of Profusa’s then issued and outstanding common shares; and (ii) the remainder of the consideration in the form of shares of Profusa non-voting convertible preferred stock (the “Preferred Stock”), which will be convertible into Profusa common shares subject to a stockholder approval by Profusa’s stockholders (together, the “Consideration”). In addition, it is expected that Profusa’s outstanding convertible notes and obligations will also be exchanged for Preferred Stock.

Concurrently with the closing of the transaction and subject to due diligence and documentation, Profusa expects to close on approximately $7 million of necessary financing (subordinated to existing bank debt) in the form a convertible note (the “Notes”), all or portions of which may be provided by existing investors in Profusa. Indicative terms of the Notes include a 12-month term, a 9% original issue discount (OID), and a 7% interest rate per year (18% in the event of a default).

About Profusa

Profusa is a digital health company developing a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its long-lasting, injectable, and affordable biosensors and intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on. For more information, please visit www.profusa.com.

“LUMEE”, “PROFUSA” and the PROFUSA logo are registered trademarks of Profusa, Inc. in the United States, Canada, European Union, China, Japan, South Korea, and Australia.

About the Dx Company

The Dx Company provides laboratory testing solutions, clinical insight, and reporting tools that help healthcare teams make informed treatment decisions, streamline workflows, and improve patient outcomes. Its CLIA-certified and CAP/CLIA accredited national medical laboratories provide molecular diagnostic tests for infectious disease and urine and blood clinical toxicology testing, with a client base serving addiction treatment, pain management, and behavioral health providers across the country.

Special Note Regarding Forward-Looking Statements

Certain statements in this press release may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or future financial or operating performance of Profusa, including statements regarding the proposed acquisition, the anticipated launch of PanOmics DX™, Profusa’s strategic plans, the proposed business combination with the Dx Company, the expected operating results of the Dx Company, the terms and amounts of the financings expected to be consummated in connection with the Dx business combination. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “propose,” “seek,” “should,” “strive,” “will,” or “would” or the negatives of these terms or variations of them or similar terminology.

Such forward-looking statements are subject to risks, uncertainties, and other factors which may be beyond the control of Profusa and could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including, without limitation, risks related to Profusa’s planned European and U.S. product launches, the risk that such product launches may not result in revenue at the levels anticipated, the risk that customer demand may be less than expected, the risks in negotiating, concluding and closing definitive acquisition agreements, as well as the risks in complying with the representations, warranties and covenants set forth in those agreements if they are executed, and risks related to the completion and terms of the contemplated financings.

These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Profusa and its management, are inherently uncertain. There are risks and uncertainties described more fully in Profusa’s public filings from time to time with the U.S. Securities and Exchange Commission (the “SEC”), including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Profusa cannot assure you that the forward-looking statements in this communication will prove to be accurate.

Investor and Media Contact
[email protected]
212-655-0924
#   #   #